Venus Remedies

Venus Remedies

509.05
-10.35
(-1.99%)
ann
Q1 Quarterly Results are out. Check out the updated financials2 days ago
Viewcross
right
Market Cap
694.30 Cr
EPS
33.90
PE Ratio
14.85
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
567.80
52 Week Low
270.25
PB Ratio
1.24
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Venus Remedies reported consolidated net profit of 96 million rupees in Q1, significantly higher than 12 million rupees in the same period last year. The company's revenue grew to 1.32 billion rupees compared to 1.09 billion rupees year-over-year, representing growth in both profitability and top-line performance.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,632.10
#1 3,93,874.80
34.32
#1 54,729.00
9.71
#1 10,980
-19.84
38.12
6,409.00
1,72,275.80
78.70
9,712.00
0.89
2,191
23.05
37.07
1,499.80
1,22,375.80
22.70
28,409.50
7.12
5,291
9.88
47.35
3,589.20
1,22,273.60
60.55
11,539.40
6.99
1,911
19.91
57.20
2,618.90
1,08,502.30
57.39
12,744.20
#1 20.90
2,007
-18.14
59.83
1,214.80
1,02,235.00
#1 18.00
33,741.20
16.73
5,725
1.26
35.34
960.25
96,482.70
20.78
23,511.00
13.82
4,615
-0.19
45.57
1,864.50
85,959.20
26.48
22,909.50
19.94
3,306
#1 112.49
37.91
33,255.00
72,237.00
51.12
6,684.70
10.80
1,414
27.83
45.87
1,079.30
63,330.60
18.34
31,378.10
17.55
3,366
-10.24
37.94
Forecast
Actual
Growth Rate
Revenue Growth
9.10 %
Net Income Growth
58.95 %
Cash Flow Change
131.80 %
ROE
38.36 %
ROCE
51.90 %
EBITDA Margin (Avg.)
8.79 %

Quarterly Financial Results

Quarterly Financials
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
68
92
77
95
75
89
99
84
191
146
128
135
132
205
126
145
145
142
121
159
97
171
146
199
110
178
189
202
141
Expenses
57
72
71
98
64
75
86
84
177
115
104
107
113
175
112
137
129
127
109
131
85
150
131
176
97
163
159
166
122
EBITDA
11
19
6
-3
11
14
13
0
13
31
24
29
19
30
14
8
16
15
12
28
13
21
14
23
13
16
30
36
19
Operating Profit %
15 %
18 %
6 %
-8 %
13 %
14 %
11 %
-2 %
6 %
8 %
15 %
4 %
13 %
13 %
10 %
4 %
10 %
9 %
7 %
16 %
11 %
11 %
8 %
10 %
10 %
3 %
10 %
15 %
8 %
Depreciation
9
9
9
9
9
9
9
7
9
9
9
9
9
9
9
8
8
9
7
8
8
6
7
6
6
6
5
5
6
Interest
8
11
10
0
6
5
4
-2
3
7
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
-6
-0
-12
-12
-4
1
0
-5
2
15
14
18
10
22
5
0
8
6
5
20
5
14
8
18
7
9
25
31
13
Tax
0
-1
-1
-0
0
0
1
1
0
2
2
-17
-2
-2
-1
0
1
0
1
9
4
4
1
7
6
6
5
10
3
Net Profit
-6
0
-12
-12
-4
0
-1
-5
2
13
12
35
12
23
6
0
7
5
3
11
1
10
7
11
1
4
20
21
10
EPS in ₹
-4.70
0.34
-9.50
-9.29
-3.30
0.34
-0.78
-4.38
1.60
10.55
9.44
28.45
8.86
17.32
4.22
0.17
5.16
3.99
2.46
8.27
0.88
7.44
5.13
7.86
0.92
2.63
14.66
15.71
7.18

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
841
843
765
751
733
644
556
580
601
627
716
Fixed Assets
444
453
406
389
364
289
262
241
216
219
229
Current Assets
233
277
259
260
265
294
234
278
323
360
452
Capital Work in Progress
78
80
66
65
65
25
25
25
26
21
26
Investments
0
0
0
0
0
0
0
0
20
19
84
Other Assets
319
310
293
297
304
330
269
314
339
368
376
Total Liabilities
841
843
765
751
733
644
556
580
601
627
716
Current Liabilities
163
193
197
230
264
225
97
93
83
79
136
Non Current Liabilities
222
212
180
159
137
96
58
47
58
60
19
Total Equity
457
438
389
362
333
323
400
440
460
488
561
Reserve & Surplus
445
426
376
350
320
311
374
427
447
474
548
Share Capital
11
11
12
12
12
12
12
13
13
13
13

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-1
4
-4
0
-1
-0
27
14
-22
28
9
Investing Activities
-67
3
-18
9
-11
-5
57
-17
-58
-9
-77
Operating Activities
68
47
59
31
45
78
132
41
37
37
86
Financing Activities
-1
-46
-44
-39
-35
-73
-162
-10
-1
-1
-1

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
35.89 %
40.81 %
40.81 %
40.81 %
40.81 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
41.76 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
1.03 %
1.59 %
1.48 %
1.06 %
1.18 %
1.11 %
1.34 %
2.24 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.15 %
0.00 %
0.00 %
0.11 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
54.71 %
51.21 %
51.95 %
52.18 %
51.72 %
49.97 %
50.18 %
50.04 %
49.24 %
48.66 %
48.20 %
47.25 %
46.89 %
46.25 %
45.31 %
45.42 %
46.81 %
47.70 %
Others
9.39 %
7.98 %
7.24 %
7.01 %
7.48 %
8.27 %
7.91 %
8.05 %
8.85 %
9.43 %
8.86 %
9.24 %
9.73 %
10.78 %
11.61 %
11.71 %
10.09 %
8.19 %
No of Share Holders
13,829
13,846
16,617
18,231
19,952
21,189
22,015
22,243
21,719
20,498
19,267
19,560
19,913
19,614
19,557
19,771
19,982
19,307

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
22 Aug 2025 431.95 519.40
01 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
01 Aug 2025 540.15 524.40
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 344.05 355.60
04 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
04 Feb 2025 294.10 288.35
29 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 Oct 2024 345.90 343.60
23 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
23 Sept 2024 339.15 342.30

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 days ago
Unaudited Financial Results For The Quarter Ended On 30Th June 20254 days ago
Board Meeting Outcome for Outcome Of Board Meeting Dated 1St August 2025.4 days ago
Social Media Communication Regarding Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares Of Venus Remedies Limited7 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication10 days ago
Reg. 34 (1) Annual Report.Jul 24, 2025
Notice Of Annual General Meeting Dated 22Nd August 2025.Jul 24, 2025
Board Meeting Intimation for Notice Of Board Meeting Dated 1St August 2025.Jul 22, 2025
Update On Trading In Shares Of Venus Remedies Ltd.Jul 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 11, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated 8Th July 2025.Jul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Board Meeting Intimation for Notice Of Board Meeting To Be Held On 8Th July 2025Jun 27, 2025
Closure of Trading WindowJun 24, 2025
Closure of Trading WindowJun 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 26, 2025
Audited Financial Results As On 31.03.2025May 26, 2025
Board Meeting Outcome for Outcome Of Board Meeting Dated 26.05.2025.May 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
Board Meeting Intimation for The Meeting Of Board Of Directors Is Scheduled To Be Held On 26Th May 2025. May 17, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 22, 2025
Change In Email Address Of RTAApr 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Closure of Trading WindowMar 24, 2025
Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To Develop And Commercialize MET-X In IndiaFeb 25, 2025
Venus Remedies Gets Market Authorization For Anticoagulant Enoxaparin From IndonesiaFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Integrated Filing (Financial)Feb 05, 2025
Intimation Under Regulation 30Feb 04, 2025
Unaudited Financial Results As On 31.12.2024Feb 04, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 04, 2025
Board Meeting Intimation for Board Meeting Scheduled To Be Held On 04Th February 2025Jan 24, 2025
Venus Remedies Limited Successfully Renews EU GMPJan 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Venus Remedies Limited Expands Reach In Eastern European Market With Accreditation Of Good Manufacturing Practice (GMP ) Certification From Ministry Of Health Of MoldovaDec 31, 2024
Venus Remedies Secures Marketing Authorization In PhilippinesDec 06, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 29, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 30, 2024
Financial Results As On 30.09.2024Oct 29, 2024
Board Meeting Outcome for Outcome Of Board Meeting Dated 29.10.24Oct 29, 2024
Board Meeting Intimation for Boar Meeting Is Scheduled For 29Th October 2024.Oct 18, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 05, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementSep 30, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 24, 2024
Closure of Trading WindowSep 24, 2024

Technical Indicators

RSI(14)
Neutral
59.01
ATR(14)
Less Volatile
17.42
STOCH(9,6)
Neutral
50.07
STOCH RSI(14)
Oversold
7.87
MACD(12,26)
Bearish
-2.92
ADX(14)
Strong Trend
27.59
UO(9)
Bearish
52.20
ROC(12)
Downtrend But Slowing Down
-6.01
WillR(14)
Neutral
-70.92